USFDA issues 8 observations for Natco Pharma Hyderabad unit

October 20, 2023
News
50 secs read

The USFDA conducted the inspection, at the company’s pharma division located in Kothur in Hyderabad, from October 9, 2023 to October 18, 2023.

Natco Pharma share price fell 1 percent in early trade on October 20 after the United States Food and Drug Administration (USFDA) issued 8 observations for its Hyderabad unit. At 09:22 hrs Natco Pharma was quoting at Rs 824.00, down Rs 9.75, or 1.17 percent on the BSE. The USFDA completed the inspection at the company’s pharma division located in Kothur in Hyderabad.

The USFDA conducted the inspection from October 9, 2023 to October 18, 2023.

The company is confident of addressing all the observations within the stipulated time and is working with the USFDA to close them at the earliest.

*Advertisement

Catch all market action in our live blog

In September, company was named as a defendant in an antitrust lawsuit in the United States. The lawsuit was filed against Natco Pharma by Louisiana Health Service and Indemnity Company and HMO Louisiana regarding pomalidomide, a drug used in treating cancer. However, the company has not disclosed any further details.

Pharmaways

Pharmaways Global Private Limited is a company established in 2022. Headed by a group of professionals with over 25 years of experience. A team of professionals who have excelled in their respective fields of Pharma, Legal & Information Technology. We have global exposure and hands-on experience of the global Pharma industry. We are in pursuit of bringing the global Pharma Industry on a platform where they can connect, collaborate and work towards mutual growth. We have taken a step into the future by innovating a technology that will help global Pharma players to empower, excel and accelerate in their business. A platform that has been developed exclusively for the Pharma fraternity. We are a New Delhi based company with overseas offices in America and the United Kingdom.